Prescription Medicines
Amycin Tab.
- Product Category
- Broad-spectrum macrolide antibiotics
- Active Ingredients
- Azithromycin
- Appearance
- A white, oblong, film-coated tablet.
- Reimbursement Code
- 648104720
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Azithromycin hydrate (EP) ········ 262.03mg (250mg as azithromycin)
- Additives: Sodium lauryl sulfate, anhydrous calcium hydrogen phosphate, magnesium stearate, Opadry white (03B28796), pregelatinized starch, croscarmellose sodium
2. Effectiveness
○ Effective bacterial species
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic), other streptococci, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Bacteroides fragilis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Haemophilus ducreyi, Neisseria gonorrhoeae, Chlamydia trachomatis, Legionella pneumophila, Mycoplasma pneumoniae, Mycoplasma hominis, Campylobacter, Toxoplasma gondii and Treponema pallidum
○ Indications
- Lower respiratory tract infections such as bronchitis and pneumonia
- Upper respiratory tract infections such as sinusitis, pharyngitis, tonsillitis, etc.
- Skin and soft tissue infections
- Otitis media
- Simple genital infection caused by Chlamydia trachomatis
3. Dosage and dosage
○ Adult
1) Sexually transmitted disease caused by Chlamydia trachomatis: Administer 1g (potency) as azithromycin once.
2) Other indications
- 3-day therapy: As azithromycin, administer 500 mg (titer) once a day for 3 days [total dose 1.5 g (titer)].
- 5-day regimen: 500mg (potency) administered once on the first day.
From the second day, administer 250mg (titer) once a day for 4 days [total dose 1.5g (titer)].
○ Children (over 45kg)
Administer the same as the adult dose.
○ Elderly people
Administer in the same manner as for adults.
4. Precautions for use
1. Warning
1) Hypersensitivity reactions: As with erythromycin and other macrolides, serious allergic reactions including angioedema or anaphylaxis (rarely fatal) and skin reactions including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis (rarely fatal), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been rarely reported. There is. Some of these reactions to this drug may result in recurrence of symptoms, requiring long-term observation and treatment. If an allergic reaction occurs, drug administration should be discontinued and appropriate therapy should be initiated. Practitioners should keep in mind that allergic symptoms may relapse if symptomatic treatment is discontinued.
2) Diarrhea caused by Clostridium difficile: Clostridium difficile associated diarrhea (CDAD) has been reported for almost all antibacterial agents, including azithromycin, with adverse reactions ranging from mild diarrhea to fatal colitis. When treated with antibacterial agents, the normal flora of the large intestine is changed by overproliferating Clostridium difficile.
Clostridium difficile produces toxin A and toxin B, which promote CDAD. Hypertoxin-producing Clostridium difficile strains increase morbidity and mortality, and in these cases, they may develop resistance to antibiotic therapy or require colectomy. CDAD should be considered in all patients who develop diarrhea after receiving antibiotics. CDAD may be reported even after 2 months or more after taking antibacterial drugs, so careful observation is necessary.
Once CDAD is suspected or diagnosed, use of antibiotics that do not directly act against Clostridium difficile needs to be discontinued. Additionally, measures such as appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment for Clostridium difficile, and surgical procedures should be initiated according to clinical need.
2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug, erythromycin, or other macrolide or ketolide antibiotics
2) Patients taking ergot alkaloids (may cause peripheral vasospasm, limb ischemia, and sensory impairment).
3. Administer with caution to the following patients:
1) Patients with renal impairment with a glomerular filtration rate (GFR) of less than 10 mL/min (systemic exposure to azithromycin increased by 33% in patients with renal impairment with a GFR of less than 10 mL/min.)
2) Patients with severe hepatic impairment (As the main metabolic route of azithromycin is the liver, caution should be exercised when administering it to these patients. Abnormal liver function, hepatitis, cholestasis jaundice, liver necrosis, and loss of liver function have been reported, some of which have led to death. If signs and symptoms of hepatitis occur, azithromycin administration should be immediately discontinued.)
4. Adverse reactions
Azithromycin is well tolerated and has a low incidence of adverse reactions.
1) The following adverse reactions were reported in clinical trials:
(1) Blood system: Temporary phenomenon of mild neutrophil reduction was occasionally observed during clinical trials.
(2) Ear and labyrinth: Hearing impairment, including hearing loss, deafness, and/or tinnitus, has been reported in some patients taking this drug, many of which are related to the long-term use of high doses in research phase clinical trials. In cases where additional information was available through follow-up, most of these adverse events were reversible.
(3) Digestive system: Nausea, vomiting, diarrhea, loose stools, abdominal discomfort (pain/cramps), and abdominal bloating have been reported.
(4) Liver: Abnormalities in liver function have been reported.
(5) Skin: Allergic reactions including rash and angioedema have been reported.
2) The following additional adverse reactions were reported through post-marketing experience:
(1) Internal and surface infections: moniliasis and vaginitis have been reported.
(2) Blood system: Since a decrease in platelets, leukocytes, and granulocytes may occur, observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
(3) Hypersensitivity reaction: As shock and anaphylactoid symptoms (difficulty breathing, angioedema, etc.) may occur, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures taken.
(4) Metabolic and nutritional abnormalities: loss of appetite has been reported.
(5) Psychological nervous system: Aggressive reactions, nervousness, excitement, and anxiety have been reported.
(6) Nervous system: Dizziness, convulsions, headache, hyperkinesia, paresthesia, drowsiness (sleeping), hypoesthesia and syncope, and rarely, loss and/or loss of taste/smell have been reported.
(7) Ear and labyrinth abnormalities: hearing loss, tinnitus, hearing impairment, and dizziness have been reported.
(8) Circulatory system: Arrhythmias including palpitations and ventricular tachycardia have been reported. QT prolongation and torsades de pointes have been reported rarely.
(9) Vascular abnormalities: hypotension has been reported.
(10) Digestive system: Vomiting, diarrhea (rarely resulting in dehydration), indigestion, constipation, pseudomembranous enteritis, pancreatitis, pyloric stenosis, and tongue discoloration have been rarely reported.
(11) Liver: Hepatitis, jaundice, and cholestatic jaundice have been reported, and in rare cases, liver necrosis and liver dysfunction have been reported. In very rare cases, this has resulted in death.
(12) Skin and subcutaneous tissue: Allergic reactions such as itching, rash, photosensitivity, edema, urticaria, and angioedema. Severe skin adverse reactions, including erythema multiforme, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), have been rarely reported. If abnormalities are recognized, discontinue administration and take appropriate measures, such as administration of corticosteroids. These adverse reactions may occur during or within 1 week after administration of this drug, so caution should be exercised even after administration.
(13) Musculoskeletal and connective tissue: Joint pain has been reported. In addition, since rhabdomyolysis may occur, sufficient observation should be conducted. If muscle pain, feelings of exhaustion, elevated CK (CPK), or elevated myoglobin in the blood or urine appear, administration should be stopped and appropriate measures should be taken. Be careful of the development of acute renal failure due to rhabdomyolysis.
(14) Kidney: Interstitial nephritis and acute renal failure have been reported.
(15) Systemic abnormalities and administration site conditions: Asthenia has been reported. fatigue, boredom
(16) Interstitial pneumonia, eosinophilic pneumonia: Interstitial pneumonia and eosinophilic pneumonia accompanied by fever, cough, difficulty in breathing, abnormal chest Also, be careful because it may appear even a few days after the end of administration.
5. General precautions
1) Superinfection: As with other antibiotic therapies, superinfection with non-susceptible strains, including fungi, may occur during administration of this drug, so observation for symptoms of superinfection is recommended.
2) Ergot derivatives: There have been cases where ergot intoxication suddenly appeared in patients taking ergot derivatives due to the combined use of some macrolide antibiotics. There are no data on the possibility of interaction between this drug and ergot, but theoretically, because of the possibility of ergot poisoning, this drug and ergot derivatives should not be used together.
3) Prolongation of the QT interval: When macrolide drugs, including azithromycin, were administered, cardiac repolarization and prolongation of the QT interval, which increases the risk of cardiac arrhythmia and torsades de pointes, were observed. thus. The risk of QT prolongation, which can be fatal, should be considered when assessing the risks and benefits of azithromycin when prescribing it to patients at high risk for the following:
(1) Patients with congenital or known QT prolongation
(2) Patients currently receiving drugs known to prolong the QT interval, such as antiarrhythmic drugs (class IA, class III), antipsychotics, antidepressants, and fluoroquinolones
(3) Patients with electrolyte disorders, especially hypokalemia and hypomagnesemia
(4) Patients clinically related to bradycardia, cardiac arrhythmia, and heart failure
(5) Elderly patients: Elderly patients may be susceptible to drug-related effects on the QT interval.
Cardiac Electrophysiology: QTc interval prolongation was studied in a randomized, placebo-controlled, parallel-group clinical trial in 116 healthy subjects receiving chloroquine (1,000 mg) alone or in combination with azithromycin (500 mg, 1,000 mg, or 1,500 mg once daily). Co-administration with azithromycin prolonged the QTc interval in a dose- and concentration-dependent manner. When 500 mg, 1,000 mg, and 1,500 mg of azithromycin were co-administered, the maximum mean QTcF (upper limit of the 95% confidence interval) increased by 5 (10) ms, 7 (12) ms, and 9 (14) ms, respectively, compared to when chloroquine was administered alone.
4) Myasthenia gravis
In patients taking this drug, worsening of myasthenia gravis symptoms and the development of new myasthenia gravis syndrome have been reported.
5) When administering this drug, instruct the patient in advance on the following matters.
(1) If symptoms suspected of Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, and drug reaction with systemic symptoms (DRESS) (symptoms such as rash, swelling or swelling of the mucous membranes (lips, eyes, vulva)) appear, stop administration and immediately consult a doctor.
(2) This drug has a long half-life in the tissue, so there is a possibility that adverse reactions may recur even a few days after the end of administration. Therefore, exercise caution, such as sufficient observation, and consult a doctor immediately if symptoms appear.
6) As a result of clinical trials, when azithromycin tablets were administered with a high-fat diet, Cmax increased by 23% from 0.336 mg/L to 0.412 mg/L due to food, and in the case of azithromycin suspension, Cmax increased by 61% from 0.294 mg/L to 0.474 mg/L, but both agents had no significant effect on AUC and bioavailability. didn't
7) Infantile hypertrophic pyloric stenosis
When this drug is used in neonates (administration up to 42 days of age), infantile hypertrophic pyloric stenosis has been reported. Parents and guardians should be informed to seek medical attention if vomiting or hypersensitivity occurs during breastfeeding.
6. Interaction
1) Antacid: In a pharmacokinetic test to determine the effect of simultaneous administration of this drug and antacid, there was no effect on overall bioavailability, but the maximum serum concentration decreased by approximately 24%. For patients taking this drug and antacids together, the two drugs should not be taken at the same time.
2) Cetirizine: When this drug was administered to healthy volunteers as a 5-day regimen and co-administered with 20 mg of cetirizine, no pharmacokinetic interactions were observed at steady state and no significant changes were observed in the QT interval.
3) Didanosine: When 1,200 mg/day of this drug was co-administered with didanosine 400 mg/day to 6 HIV-positive patients, it did not appear to affect the pharmacokinetics of didanosine compared to placebo.
4) Digoxin and Colchicine: When macrolide antibiotics, including azithromycin, are co-administered with P-glycoprotein substrates such as digoxin and colchicine, an increase in the serum concentration of P-glycoprotein substrates has been reported. Therefore, when coadministering azithromycin and P-gp substrates such as digoxin, the possibility that the serum concentration of digoxin may increase should be considered. Digoxin serum concentration levels and clinical monitoring are required during concurrent use with azithromycin and after discontinuation of concurrent use.
5) Zidovudine: Single administration of 1,000 mg of this drug or repeated administration of 1,200 mg or 600 mg had little effect on the plasma pharmacokinetics and urinary excretion of zidovudine or glucuronide metabolites. However, the concentration of the clinically active metabolite, zidovudine phosphate, in peripheral blood mononuclear cells was increased by administration of this drug. The clinical significance of these results is unclear, but they may be beneficial to patients.
6) This drug does not show significant interaction with the liver cytochrome P450 enzyme system. It is not thought to have pharmacokinetic drug interactions similar to those observed with erythromycin and other macrolide drugs. Induction or inactivation of the hepatic cytochrome P450 enzyme system via cytochrome-metabolite complexes has not been shown with this drug.
7) Ergot: Theoretically, there is a possibility of interaction between this drug and ergot derivatives.
8) A pharmacokinetic test was conducted between this drug and the following drugs known to be significantly metabolized by cytochrome P450.
(1) Atorvastatin: The combined use of atorvastatin (10 mg/day) and this drug (500 mg/day) does not change the plasma concentration of atorvastatin (based on the results of HM G CoA-reductase inhibition as say). However, post-marketing cases such as rhabdomyolysis have been reported in patients receiving azithromycin together with statins.
(2) Carbamazepine: As a result of a pharmacokinetic test conducted on healthy volunteers, it was observed that the plasma concentration of carbamazepine or its active metabolite was not significantly affected in patients taking this drug in combination with carbamazepine.
(3) Cimetidine: In a pharmacokinetic test to determine the effect of administering a single dose of cimetidine 2 hours before administration of this drug on the pharmacokinetics of this drug, no changes were observed in the pharmacokinetics of this drug.
(4) Efavirenz: When efavirenz 400 mg/day was administered for 7 days in combination with a single dose of 600 mg of this drug, no clinically significant pharmacokinetic interaction was observed.
(5) Coumarin oral anticoagulants: In a test to determine pharmacokinetic drug interactions, when 15 mg of warfarin was administered once to healthy volunteers, this drug did not affect the anticoagulant effect of warfarin. During the post-marketing period, there were reports that the anticoagulant effect increased after coadministration of this drug and coumarin-based oral anticoagulants. Although the causal relationship has not been proven, the frequency of monitoring the prothrombin time should be considered when administering this drug to patients taking coumarin-based oral anticoagulants.
(6) Cyclosporine: In a pharmacokinetic study conducted on healthy volunteers, a single dose of cyclosporine 10 mg/kg was administered after oral administration of 500 mg/day of this drug for 3 days, and a significant increase in cyclosporine Cmax and AUC0-5 was observed. Therefore, caution should be exercised before considering coadministration of these drugs. If co-administration of these drugs is necessary, the concentration of cyclosporine should be monitored and the dose adjusted accordingly.
(7) Fluconazole: When 1,200 mg of this drug was administered as a single dose in combination with a single dose of 800 mg of fluconazole, there was no change in the pharmacokinetics of fluconazole. There was no change in the total drug exposure and half-life of this drug due to co-administration with fluconazole, but a clinically insignificant decrease in Cmax was observed.
(8) Indinavir: When 800 mg of indinavir was administered three times a day for 5 days and a single dose of 1,200 mg of this drug was administered concurrently, there was no statistically significant effect on the pharmacokinetics of indinavir.
(9) Methylprednisolone: Pharmacokinetic tests conducted on healthy volunteers showed that this drug did not have any significant effect on the pharmacokinetics of methylprednisolone.
(10) Midazolam: When 500 mg/day of this drug was administered for 3 days and a single dose of 15 mg midazolam was administered to healthy volunteers, there were no clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.
(11) Nelfinavir: When 1,200 mg of azithromycin and steady-state nelfinavir (750 mg administered three times a day) were administered together, the blood concentration of this drug increased. No clinically significant adverse reactions were observed and no dose adjustment is necessary.
(12) Rifabutin: The combined use of azithromycin and rifabutin had no effect on the plasma concentrations of both drugs. A decrease in neutrophils was observed in patients who took the two drugs together. Neutrophil reduction is related to the administration of rifabutin, but a causal relationship with concurrent use of this drug has not been proven.
(13) Sildenafil: In healthy normal male volunteers, there was no evidence that this drug (500 mg/day for 3 days) had any effect on the AUC and Cmax of sildenafil or its major metabolites.
(14) Terfenadine: There is no evidence of interaction between this drug and terfenadine reported through pharmacokinetic studies. There have been rare reports in which the possibility of such an interaction cannot be completely ruled out, but there has been no concrete evidence that the interaction has occurred.
(15) Theophylline: There is no evidence of clinically significant pharmacokinetic interactions when this drug and theophylline were administered together in healthy volunteers.
(16) Triazolam: When 500 mg of this drug was administered on the first day to 14 healthy volunteers and 250 mg of this drug and 0.125 mg of triazolam were co-administered on the next day, it was found that there was no significant effect on any of the pharmacokinetic variables of triazolam as a result of comparison with the case of co-administration of placebo and triazolam.
(17) Trimethoprim/sulfamethoxazole: When trimethoprim/sulfamethoxazole DS (Double Strength, 160 mg/800 mg) is administered for 7 days and 1,200 mg of this drug is co-administered on the 7th day of drug administration, there is no significant effect on the peak blood concentration, total drug exposure, or urinary excretion of trimethoprim or sulfamethoxazole. didn't Serum concentrations of this drug were similar to those observed in other studies.
7. Administration to pregnant and lactating women
1) Pregnant women: According to reproductive toxicity tests in animals, it was confirmed that this drug passes through the placenta, but there is no evidence that it has a harmful effect on the fetus. Safety for use during pregnancy in humans has not been established. There is a large body of data on exposure to azithromycin during pregnancy from observational studies conducted in several countries, compared with no antibiotic use or use of other antibiotics during the first trimester. Most studies do not suggest an association with adverse fetal effects, such as major congenital malformations or cardiovascular malformations, after azithromycin exposure during early pregnancy, and there is limited epidemiological evidence of an increased risk of miscarriage.
Azithromycin should be used during pregnancy only when suitable alternatives are not available and the therapeutic benefit is expected to outweigh the potential increased risks.
2) Nursing mothers: According to literature, azithromycin passes into human breast milk. Considering the benefit of breastfeeding and the therapeutic benefit to the mother, a decision should be made to discontinue breastfeeding or discontinue treatment with this drug.
3) Fertility: In a fertility study conducted on rats, a decrease in the pregnancy rate was found following azithromycin administration. The relevance of these findings to humans is unknown.
8. Administration to elderly people
For elderly patients, administer the same dose as for adult patients. Elderly patients may be more susceptible to the development of torsades de pointes arrhythmias than younger patients.
9. Treatment in case of overdose
Adverse reactions occurring at doses above the recommended dose were similar to those observed when taking the recommended dose. In case of overdose, general symptomatic and supportive care is administered.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
11. Pharmaceutical equivalence test information
The test drug Amamicin Tablets 250 mg (azithromycin hydrate) [KyungDong Pharm Co., Ltd.] and the control drug Zithromax Tablets 250 mg (azithromycin hydrate) [Korea Pfizer Pharmaceuticals Co., Ltd.] were administered orally once on an empty stomach to healthy adults in a 2 When the item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
12. How to save
Airtight container, stored below 25℃
13. Packaging unit
30 tablets (10 tablets/PTPX3)
14. Validity period
36 months from date of manufacture
1 tablet
- Active ingredient: Azithromycin hydrate (EP) ········ 262.03mg (250mg as azithromycin)
- Additives: Sodium lauryl sulfate, anhydrous calcium hydrogen phosphate, magnesium stearate, Opadry white (03B28796), pregelatinized starch, croscarmellose sodium
2. Effectiveness
○ Effective bacterial species
Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes (group A beta-hemolytic), other streptococci, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Bacteroides fragilis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Haemophilus ducreyi, Neisseria gonorrhoeae, Chlamydia trachomatis, Legionella pneumophila, Mycoplasma pneumoniae, Mycoplasma hominis, Campylobacter, Toxoplasma gondii and Treponema pallidum
○ Indications
- Lower respiratory tract infections such as bronchitis and pneumonia
- Upper respiratory tract infections such as sinusitis, pharyngitis, tonsillitis, etc.
- Skin and soft tissue infections
- Otitis media
- Simple genital infection caused by Chlamydia trachomatis
3. Dosage and dosage
○ Adult
1) Sexually transmitted disease caused by Chlamydia trachomatis: Administer 1g (potency) as azithromycin once.
2) Other indications
- 3-day therapy: As azithromycin, administer 500 mg (titer) once a day for 3 days [total dose 1.5 g (titer)].
- 5-day regimen: 500mg (potency) administered once on the first day.
From the second day, administer 250mg (titer) once a day for 4 days [total dose 1.5g (titer)].
○ Children (over 45kg)
Administer the same as the adult dose.
○ Elderly people
Administer in the same manner as for adults.
4. Precautions for use
1. Warning
1) Hypersensitivity reactions: As with erythromycin and other macrolides, serious allergic reactions including angioedema or anaphylaxis (rarely fatal) and skin reactions including acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis (rarely fatal), and drug reaction with eosinophilia and systemic symptoms (DRESS) have been rarely reported. There is. Some of these reactions to this drug may result in recurrence of symptoms, requiring long-term observation and treatment. If an allergic reaction occurs, drug administration should be discontinued and appropriate therapy should be initiated. Practitioners should keep in mind that allergic symptoms may relapse if symptomatic treatment is discontinued.
2) Diarrhea caused by Clostridium difficile: Clostridium difficile associated diarrhea (CDAD) has been reported for almost all antibacterial agents, including azithromycin, with adverse reactions ranging from mild diarrhea to fatal colitis. When treated with antibacterial agents, the normal flora of the large intestine is changed by overproliferating Clostridium difficile.
Clostridium difficile produces toxin A and toxin B, which promote CDAD. Hypertoxin-producing Clostridium difficile strains increase morbidity and mortality, and in these cases, they may develop resistance to antibiotic therapy or require colectomy. CDAD should be considered in all patients who develop diarrhea after receiving antibiotics. CDAD may be reported even after 2 months or more after taking antibacterial drugs, so careful observation is necessary.
Once CDAD is suspected or diagnosed, use of antibiotics that do not directly act against Clostridium difficile needs to be discontinued. Additionally, measures such as appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment for Clostridium difficile, and surgical procedures should be initiated according to clinical need.
2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug, erythromycin, or other macrolide or ketolide antibiotics
2) Patients taking ergot alkaloids (may cause peripheral vasospasm, limb ischemia, and sensory impairment).
3. Administer with caution to the following patients:
1) Patients with renal impairment with a glomerular filtration rate (GFR) of less than 10 mL/min (systemic exposure to azithromycin increased by 33% in patients with renal impairment with a GFR of less than 10 mL/min.)
2) Patients with severe hepatic impairment (As the main metabolic route of azithromycin is the liver, caution should be exercised when administering it to these patients. Abnormal liver function, hepatitis, cholestasis jaundice, liver necrosis, and loss of liver function have been reported, some of which have led to death. If signs and symptoms of hepatitis occur, azithromycin administration should be immediately discontinued.)
4. Adverse reactions
Azithromycin is well tolerated and has a low incidence of adverse reactions.
1) The following adverse reactions were reported in clinical trials:
(1) Blood system: Temporary phenomenon of mild neutrophil reduction was occasionally observed during clinical trials.
(2) Ear and labyrinth: Hearing impairment, including hearing loss, deafness, and/or tinnitus, has been reported in some patients taking this drug, many of which are related to the long-term use of high doses in research phase clinical trials. In cases where additional information was available through follow-up, most of these adverse events were reversible.
(3) Digestive system: Nausea, vomiting, diarrhea, loose stools, abdominal discomfort (pain/cramps), and abdominal bloating have been reported.
(4) Liver: Abnormalities in liver function have been reported.
(5) Skin: Allergic reactions including rash and angioedema have been reported.
2) The following additional adverse reactions were reported through post-marketing experience:
(1) Internal and surface infections: moniliasis and vaginitis have been reported.
(2) Blood system: Since a decrease in platelets, leukocytes, and granulocytes may occur, observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
(3) Hypersensitivity reaction: As shock and anaphylactoid symptoms (difficulty breathing, angioedema, etc.) may occur, sufficient observation should be conducted and if abnormalities are recognized, administration should be discontinued and appropriate measures taken.
(4) Metabolic and nutritional abnormalities: loss of appetite has been reported.
(5) Psychological nervous system: Aggressive reactions, nervousness, excitement, and anxiety have been reported.
(6) Nervous system: Dizziness, convulsions, headache, hyperkinesia, paresthesia, drowsiness (sleeping), hypoesthesia and syncope, and rarely, loss and/or loss of taste/smell have been reported.
(7) Ear and labyrinth abnormalities: hearing loss, tinnitus, hearing impairment, and dizziness have been reported.
(8) Circulatory system: Arrhythmias including palpitations and ventricular tachycardia have been reported. QT prolongation and torsades de pointes have been reported rarely.
(9) Vascular abnormalities: hypotension has been reported.
(10) Digestive system: Vomiting, diarrhea (rarely resulting in dehydration), indigestion, constipation, pseudomembranous enteritis, pancreatitis, pyloric stenosis, and tongue discoloration have been rarely reported.
(11) Liver: Hepatitis, jaundice, and cholestatic jaundice have been reported, and in rare cases, liver necrosis and liver dysfunction have been reported. In very rare cases, this has resulted in death.
(12) Skin and subcutaneous tissue: Allergic reactions such as itching, rash, photosensitivity, edema, urticaria, and angioedema. Severe skin adverse reactions, including erythema multiforme, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), have been rarely reported. If abnormalities are recognized, discontinue administration and take appropriate measures, such as administration of corticosteroids. These adverse reactions may occur during or within 1 week after administration of this drug, so caution should be exercised even after administration.
(13) Musculoskeletal and connective tissue: Joint pain has been reported. In addition, since rhabdomyolysis may occur, sufficient observation should be conducted. If muscle pain, feelings of exhaustion, elevated CK (CPK), or elevated myoglobin in the blood or urine appear, administration should be stopped and appropriate measures should be taken. Be careful of the development of acute renal failure due to rhabdomyolysis.
(14) Kidney: Interstitial nephritis and acute renal failure have been reported.
(15) Systemic abnormalities and administration site conditions: Asthenia has been reported. fatigue, boredom
(16) Interstitial pneumonia, eosinophilic pneumonia: Interstitial pneumonia and eosinophilic pneumonia accompanied by fever, cough, difficulty in breathing, abnormal chest Also, be careful because it may appear even a few days after the end of administration.
5. General precautions
1) Superinfection: As with other antibiotic therapies, superinfection with non-susceptible strains, including fungi, may occur during administration of this drug, so observation for symptoms of superinfection is recommended.
2) Ergot derivatives: There have been cases where ergot intoxication suddenly appeared in patients taking ergot derivatives due to the combined use of some macrolide antibiotics. There are no data on the possibility of interaction between this drug and ergot, but theoretically, because of the possibility of ergot poisoning, this drug and ergot derivatives should not be used together.
3) Prolongation of the QT interval: When macrolide drugs, including azithromycin, were administered, cardiac repolarization and prolongation of the QT interval, which increases the risk of cardiac arrhythmia and torsades de pointes, were observed. thus. The risk of QT prolongation, which can be fatal, should be considered when assessing the risks and benefits of azithromycin when prescribing it to patients at high risk for the following:
(1) Patients with congenital or known QT prolongation
(2) Patients currently receiving drugs known to prolong the QT interval, such as antiarrhythmic drugs (class IA, class III), antipsychotics, antidepressants, and fluoroquinolones
(3) Patients with electrolyte disorders, especially hypokalemia and hypomagnesemia
(4) Patients clinically related to bradycardia, cardiac arrhythmia, and heart failure
(5) Elderly patients: Elderly patients may be susceptible to drug-related effects on the QT interval.
Cardiac Electrophysiology: QTc interval prolongation was studied in a randomized, placebo-controlled, parallel-group clinical trial in 116 healthy subjects receiving chloroquine (1,000 mg) alone or in combination with azithromycin (500 mg, 1,000 mg, or 1,500 mg once daily). Co-administration with azithromycin prolonged the QTc interval in a dose- and concentration-dependent manner. When 500 mg, 1,000 mg, and 1,500 mg of azithromycin were co-administered, the maximum mean QTcF (upper limit of the 95% confidence interval) increased by 5 (10) ms, 7 (12) ms, and 9 (14) ms, respectively, compared to when chloroquine was administered alone.
4) Myasthenia gravis
In patients taking this drug, worsening of myasthenia gravis symptoms and the development of new myasthenia gravis syndrome have been reported.
5) When administering this drug, instruct the patient in advance on the following matters.
(1) If symptoms suspected of Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia, and drug reaction with systemic symptoms (DRESS) (symptoms such as rash, swelling or swelling of the mucous membranes (lips, eyes, vulva)) appear, stop administration and immediately consult a doctor.
(2) This drug has a long half-life in the tissue, so there is a possibility that adverse reactions may recur even a few days after the end of administration. Therefore, exercise caution, such as sufficient observation, and consult a doctor immediately if symptoms appear.
6) As a result of clinical trials, when azithromycin tablets were administered with a high-fat diet, Cmax increased by 23% from 0.336 mg/L to 0.412 mg/L due to food, and in the case of azithromycin suspension, Cmax increased by 61% from 0.294 mg/L to 0.474 mg/L, but both agents had no significant effect on AUC and bioavailability. didn't
7) Infantile hypertrophic pyloric stenosis
When this drug is used in neonates (administration up to 42 days of age), infantile hypertrophic pyloric stenosis has been reported. Parents and guardians should be informed to seek medical attention if vomiting or hypersensitivity occurs during breastfeeding.
6. Interaction
1) Antacid: In a pharmacokinetic test to determine the effect of simultaneous administration of this drug and antacid, there was no effect on overall bioavailability, but the maximum serum concentration decreased by approximately 24%. For patients taking this drug and antacids together, the two drugs should not be taken at the same time.
2) Cetirizine: When this drug was administered to healthy volunteers as a 5-day regimen and co-administered with 20 mg of cetirizine, no pharmacokinetic interactions were observed at steady state and no significant changes were observed in the QT interval.
3) Didanosine: When 1,200 mg/day of this drug was co-administered with didanosine 400 mg/day to 6 HIV-positive patients, it did not appear to affect the pharmacokinetics of didanosine compared to placebo.
4) Digoxin and Colchicine: When macrolide antibiotics, including azithromycin, are co-administered with P-glycoprotein substrates such as digoxin and colchicine, an increase in the serum concentration of P-glycoprotein substrates has been reported. Therefore, when coadministering azithromycin and P-gp substrates such as digoxin, the possibility that the serum concentration of digoxin may increase should be considered. Digoxin serum concentration levels and clinical monitoring are required during concurrent use with azithromycin and after discontinuation of concurrent use.
5) Zidovudine: Single administration of 1,000 mg of this drug or repeated administration of 1,200 mg or 600 mg had little effect on the plasma pharmacokinetics and urinary excretion of zidovudine or glucuronide metabolites. However, the concentration of the clinically active metabolite, zidovudine phosphate, in peripheral blood mononuclear cells was increased by administration of this drug. The clinical significance of these results is unclear, but they may be beneficial to patients.
6) This drug does not show significant interaction with the liver cytochrome P450 enzyme system. It is not thought to have pharmacokinetic drug interactions similar to those observed with erythromycin and other macrolide drugs. Induction or inactivation of the hepatic cytochrome P450 enzyme system via cytochrome-metabolite complexes has not been shown with this drug.
7) Ergot: Theoretically, there is a possibility of interaction between this drug and ergot derivatives.
8) A pharmacokinetic test was conducted between this drug and the following drugs known to be significantly metabolized by cytochrome P450.
(1) Atorvastatin: The combined use of atorvastatin (10 mg/day) and this drug (500 mg/day) does not change the plasma concentration of atorvastatin (based on the results of HM G CoA-reductase inhibition as say). However, post-marketing cases such as rhabdomyolysis have been reported in patients receiving azithromycin together with statins.
(2) Carbamazepine: As a result of a pharmacokinetic test conducted on healthy volunteers, it was observed that the plasma concentration of carbamazepine or its active metabolite was not significantly affected in patients taking this drug in combination with carbamazepine.
(3) Cimetidine: In a pharmacokinetic test to determine the effect of administering a single dose of cimetidine 2 hours before administration of this drug on the pharmacokinetics of this drug, no changes were observed in the pharmacokinetics of this drug.
(4) Efavirenz: When efavirenz 400 mg/day was administered for 7 days in combination with a single dose of 600 mg of this drug, no clinically significant pharmacokinetic interaction was observed.
(5) Coumarin oral anticoagulants: In a test to determine pharmacokinetic drug interactions, when 15 mg of warfarin was administered once to healthy volunteers, this drug did not affect the anticoagulant effect of warfarin. During the post-marketing period, there were reports that the anticoagulant effect increased after coadministration of this drug and coumarin-based oral anticoagulants. Although the causal relationship has not been proven, the frequency of monitoring the prothrombin time should be considered when administering this drug to patients taking coumarin-based oral anticoagulants.
(6) Cyclosporine: In a pharmacokinetic study conducted on healthy volunteers, a single dose of cyclosporine 10 mg/kg was administered after oral administration of 500 mg/day of this drug for 3 days, and a significant increase in cyclosporine Cmax and AUC0-5 was observed. Therefore, caution should be exercised before considering coadministration of these drugs. If co-administration of these drugs is necessary, the concentration of cyclosporine should be monitored and the dose adjusted accordingly.
(7) Fluconazole: When 1,200 mg of this drug was administered as a single dose in combination with a single dose of 800 mg of fluconazole, there was no change in the pharmacokinetics of fluconazole. There was no change in the total drug exposure and half-life of this drug due to co-administration with fluconazole, but a clinically insignificant decrease in Cmax was observed.
(8) Indinavir: When 800 mg of indinavir was administered three times a day for 5 days and a single dose of 1,200 mg of this drug was administered concurrently, there was no statistically significant effect on the pharmacokinetics of indinavir.
(9) Methylprednisolone: Pharmacokinetic tests conducted on healthy volunteers showed that this drug did not have any significant effect on the pharmacokinetics of methylprednisolone.
(10) Midazolam: When 500 mg/day of this drug was administered for 3 days and a single dose of 15 mg midazolam was administered to healthy volunteers, there were no clinically significant changes in the pharmacokinetics and pharmacodynamics of midazolam.
(11) Nelfinavir: When 1,200 mg of azithromycin and steady-state nelfinavir (750 mg administered three times a day) were administered together, the blood concentration of this drug increased. No clinically significant adverse reactions were observed and no dose adjustment is necessary.
(12) Rifabutin: The combined use of azithromycin and rifabutin had no effect on the plasma concentrations of both drugs. A decrease in neutrophils was observed in patients who took the two drugs together. Neutrophil reduction is related to the administration of rifabutin, but a causal relationship with concurrent use of this drug has not been proven.
(13) Sildenafil: In healthy normal male volunteers, there was no evidence that this drug (500 mg/day for 3 days) had any effect on the AUC and Cmax of sildenafil or its major metabolites.
(14) Terfenadine: There is no evidence of interaction between this drug and terfenadine reported through pharmacokinetic studies. There have been rare reports in which the possibility of such an interaction cannot be completely ruled out, but there has been no concrete evidence that the interaction has occurred.
(15) Theophylline: There is no evidence of clinically significant pharmacokinetic interactions when this drug and theophylline were administered together in healthy volunteers.
(16) Triazolam: When 500 mg of this drug was administered on the first day to 14 healthy volunteers and 250 mg of this drug and 0.125 mg of triazolam were co-administered on the next day, it was found that there was no significant effect on any of the pharmacokinetic variables of triazolam as a result of comparison with the case of co-administration of placebo and triazolam.
(17) Trimethoprim/sulfamethoxazole: When trimethoprim/sulfamethoxazole DS (Double Strength, 160 mg/800 mg) is administered for 7 days and 1,200 mg of this drug is co-administered on the 7th day of drug administration, there is no significant effect on the peak blood concentration, total drug exposure, or urinary excretion of trimethoprim or sulfamethoxazole. didn't Serum concentrations of this drug were similar to those observed in other studies.
7. Administration to pregnant and lactating women
1) Pregnant women: According to reproductive toxicity tests in animals, it was confirmed that this drug passes through the placenta, but there is no evidence that it has a harmful effect on the fetus. Safety for use during pregnancy in humans has not been established. There is a large body of data on exposure to azithromycin during pregnancy from observational studies conducted in several countries, compared with no antibiotic use or use of other antibiotics during the first trimester. Most studies do not suggest an association with adverse fetal effects, such as major congenital malformations or cardiovascular malformations, after azithromycin exposure during early pregnancy, and there is limited epidemiological evidence of an increased risk of miscarriage.
Azithromycin should be used during pregnancy only when suitable alternatives are not available and the therapeutic benefit is expected to outweigh the potential increased risks.
2) Nursing mothers: According to literature, azithromycin passes into human breast milk. Considering the benefit of breastfeeding and the therapeutic benefit to the mother, a decision should be made to discontinue breastfeeding or discontinue treatment with this drug.
3) Fertility: In a fertility study conducted on rats, a decrease in the pregnancy rate was found following azithromycin administration. The relevance of these findings to humans is unknown.
8. Administration to elderly people
For elderly patients, administer the same dose as for adult patients. Elderly patients may be more susceptible to the development of torsades de pointes arrhythmias than younger patients.
9. Treatment in case of overdose
Adverse reactions occurring at doses above the recommended dose were similar to those observed when taking the recommended dose. In case of overdose, general symptomatic and supportive care is administered.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause accidents due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container.
11. Pharmaceutical equivalence test information
The test drug Amamicin Tablets 250 mg (azithromycin hydrate) [KyungDong Pharm Co., Ltd.] and the control drug Zithromax Tablets 250 mg (azithromycin hydrate) [Korea Pfizer Pharmaceuticals Co., Ltd.] were administered orally once on an empty stomach to healthy adults in a 2 When the item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
12. How to save
Airtight container, stored below 25℃
13. Packaging unit
30 tablets (10 tablets/PTPX3)
14. Validity period
36 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Amycin Tab. | Precautions for use | 2023.09.12 | PDFChange plan + change comparison table.pdf |